Site Search

Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance

Investment will support discovery research of a novel Gene Coding^TM approach that could benefit all people with CF regardless of their mutation
 

The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.

New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease

Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab